Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAF_FRontier-1
jRCT2051250248Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of LY4152199 in mature B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of participants with dose limiting toxicities of LY4152199. Started Apr 2026; status: recruiting.
02
Drugs
LY4152199
03
Conditions
mature B-cell lymphomadiffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on jRCT2051250248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250248.